Introduction: There is a growing need for economic evaluations describing the disease
course, as well as the costs and clinical outcomes related to the treatment of schizophrenia …

Suicide is one of the potential complications in the Schizophrenic patient population. This
review article deals with the significance of antipsychotic medication compliance in …

Background Schizophrenia is a chronic mental illness that requires lifelong antipsychotic
treatment. Therapy discontinuation, often due to poor adherence, increases the risk of …

Background To overcome nonadherence in patients with psychosis switch to long-acting
injectable (LAI) antipsychotic formulations is adopted. Most oral versus LAI comparisons …

BACKGROUND: Paliperidone is among the most cost-effective antipsychotics in adults with
schizophrenia, and it has different formulations, including oral paliperidone extended …

Purpose Cardiovascular and metabolic adverse events are costly to treat, and their
incidence is increased amongst people with schizophrenia, with different rates observed for …

Objective: The objective of this study was to describe the safety, efficacy, and potential role
in therapy of once in 6 months paliperidone palmitate formulation (PP6M; Invega Hafyera) …

Background: A new depot formulation of paliperidone has been developed that provides
effective treatment for schizophrenia for 3 months (PP3M). It has been tested in phase-3 …

Background: Schizophrenia is a severe and complex disease with substantial economic and
social burdens. Despite multiple treatment choices, adverse events, and impaired social …

Objective: This retrospective longitudinal cohort study aimed to compare treatment patterns,
healthcare resource utilization (HRU), and costs in patients with schizophrenia treated with …